C12N 15/1133
Against herpetoviridae
Official title: {against herpetoviridae, e.g. HSV}
C12N15/1133 (Against herpetoviridae) appears on 107 US grants and 122 published applications in this corpus.
Search patents in C12N- Granted patents
- 107
- Published applications
- 122
- Assignees
- 71
- Inventors
- 234
- Latest grant
- 21 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 4 | 0 |
| 1996 | 8 | 0 |
| 1997 | 11 | 0 |
| 1998 | 8 | 0 |
| 1999 | 3 | 0 |
| 2000 | 7 | 0 |
| 2001 | 5 | 0 |
| 2002 | 4 | 3 |
| 2003 | 4 | 5 |
| 2004 | 3 | 3 |
| 2005 | 1 | 3 |
| 2006 | 3 | 2 |
| 2007 | 1 | 6 |
| 2008 | 2 | 5 |
| 2009 | 0 | 6 |
| 2010 | 1 | 4 |
| 2011 | 2 | 3 |
| 2012 | 0 | 3 |
| 2013 | 1 | 0 |
| 2014 | 2 | 1 |
| 2015 | 1 | 8 |
| 2016 | 2 | 6 |
| 2017 | 3 | 8 |
| 2018 | 3 | 6 |
| 2019 | 6 | 13 |
| 2020 | 3 | 7 |
| 2021 | 5 | 7 |
| 2022 | 4 | 6 |
| 2023 | 3 | 6 |
| 2024 | 1 | 5 |
| 2025 | 2 | 1 |
| 2026 | 1 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions for herpesvirus transcriptional feedback circuit disruption and uses thereof21 Apr 2026US 12,606,829 B2The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone
- Treating herpesvirus-mediated intestinal dysfunction for prevention of age-related neurodegeneration30 Sep 2025US 12,428,643 B2Battle Biotech L.L.C.
- Oligomers and oligomer conjugates22 Apr 2025US 12,281,307 B2Hoffmann-La Roche Inc.
- Method for delivering RNA to neurons to treat herpes infections3 Dec 2024US 12,156,919 B2Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
- CRISPR/CAS-related methods and compositions for treating herpes simplex virus5 Dec 2023US 11,834,649 B2Editas Medicine, Inc.
- Method for reducing chlorophyll degradation in a plant17 Sep 2026US 2026/0275367 A1Zhejiang Wanli University
- Hepatitis b combination therapies6 Aug 2026US 2026/0226470 A1Aligos Therapeutics, Inc.
- Rna guided eradication of herpes simplex type i and other related herpesviruses16 Apr 2026US 2026/0102515 A1Temple University of the Commonwealth System of Higher Education
- Treating herpesvirus-mediated intestinal dysfunction for prevention of age-related neurodegeneration9 Apr 2026US 2026/0098267 A1Battle Biotech L.L.C.
- Oncolytic virus expressing an immune cell engager for tumor targeting19 Mar 2026US 2026/0077006 A1Virogin Biotech Canada Ltd
Most cited
By later US patents
- N-2 substituted purines806US 5,459,255 AIsis Pharmaceuticals, Inc. · 1995
- Oligonucleotides having phosphorothioate linkages of high chiral purity626US 5,587,361 AIsis Pharmaceuticals, Inc. · 1996
- Oligonucleotides containing N-2 substituted purines621US 5,587,469 AIsis Pharmaceuticals, Inc. · 1996
- Oligonucleotide-folate conjugates241US 6,528,631 B1Isis Pharmaceuticals, Inc. · 2003
- Immune stimulation by phosphorothioate oligonucleotide analogs238US 5,663,153 AIsis Pharmaceuticals, Inc. · 1997